NLRP3 and ovarian carcinoma: The abovementioned findings suggest that downregulation of NLRP3 repressed the malignant processes of DPP-resistant ovarian cancer cells, which might be beneficial to improve the antitumor effects of DDP against DDP-resistant patients with ovarian cancer.